Testing effectiveness (Phase 2)Study completedNCT03650452
What this trial is testing
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
Who this might be right for
EpilepsyDravet SyndromeLennox-Gastaut Syndrome
Takeda 141